$4.30
0.040.94%
Last update: Nov 12, 4:00 PM
Gyre Therapeutics Inc
GYRENASDAQ
Gyre Therapeutics fell 48.9% from $8.34 to $4.26, behind the S&P 500's +10.8%. Its worst day was Oct 30 (−28.9%), and its low came Nov 5 at $4.01.
Nov 12, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Gyre Pharmaceuticals completed a Pre-NDA meeting with China’s CDE, which agreed that the existing Phase 3 clinical data support a conditional approval filing for Hydronidone and priority review eligibility, subject to
+16.3% · S&P 500 +0.7%
Story events cover the past 12 months · Times ET
Gyre Therapeutics closed at its highest level of the year, 5.0% above where the year started.
+6.3% · S&P 500 +0.1%
EPS of $0.05 beat the $0.04 estimate on $37.2M revenue (est. $35.8M); FY revenue guidance of $100.5M–$111.0M against the $153.6M consensus.
−6.3% · S&P 500 −1.5%
EPS of $-0.04 beat the $-0.07 estimate on $22.5M revenue (est. $32.1M); FY revenue guidance of $100.5M–$111.0M against the $130.0M consensus.
−12.1% · S&P 500 −0.3%
Gyre Therapeutics shares rose 12.6%, while the S&P 500 fell 0.1%.
+12.6% · S&P 500 −0.1%
EPS of $-0.12 missed the $-0.06 estimate on $29.1M revenue (est. $26.4M); FY revenue guidance of $100.5M–$111.0M against the $101.9M consensus.
+4.2% · S&P 500 +0.6%
EPS of $-0.04 beat the $-0.12 estimate on $32.9M revenue (est. $28.4M); FY revenue guidance of $100.5M–$111.0M against the $109.6M consensus.
+18.7%, the year's best day · S&P 500 +0.3%
Where it ended: a close of $4.26 on Nov 11, 2026. Up next: Q4 2026 earnings on Mar 11, 2027 (EPS est. $-0.05, revenue est. $29.1M).
Nothing in the past 12 months.
All GYRE analyst actionsNothing in the past 12 months.
All GYRE dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for GYRE and SPY from Benzinga historical bars. Not investment advice.
